KR20250057022A - 4-[4-[3-클로로-4-[1-(2-피리딜)-2-히드록시-에톡시]피라졸로[1,5-a]피리딘-6-일]-5-메틸-트리아졸-1-일]피페리딘-1-카르보니트릴유도체와 갈산 및 니코틴아미드의 공-결정 - Google Patents

4-[4-[3-클로로-4-[1-(2-피리딜)-2-히드록시-에톡시]피라졸로[1,5-a]피리딘-6-일]-5-메틸-트리아졸-1-일]피페리딘-1-카르보니트릴유도체와 갈산 및 니코틴아미드의 공-결정 Download PDF

Info

Publication number
KR20250057022A
KR20250057022A KR1020257010708A KR20257010708A KR20250057022A KR 20250057022 A KR20250057022 A KR 20250057022A KR 1020257010708 A KR1020257010708 A KR 1020257010708A KR 20257010708 A KR20257010708 A KR 20257010708A KR 20250057022 A KR20250057022 A KR 20250057022A
Authority
KR
South Korea
Prior art keywords
cancer
crystalline form
urothelial
fgfr3
bladder cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020257010708A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 앤드류 코츠
로리 라켈 힐든
기슬레인 쿠미넥
제프리 에이. 피터슨
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20250057022A publication Critical patent/KR20250057022A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020257010708A 2022-09-07 2023-09-06 4-[4-[3-클로로-4-[1-(2-피리딜)-2-히드록시-에톡시]피라졸로[1,5-a]피리딘-6-일]-5-메틸-트리아졸-1-일]피페리딘-1-카르보니트릴유도체와 갈산 및 니코틴아미드의 공-결정 Ceased KR20250057022A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263404232P 2022-09-07 2022-09-07
US63/404,232 2022-09-07
PCT/US2023/073508 WO2024054814A1 (en) 2022-09-07 2023-09-06 Co-crystals of 4-[4-[3-chloro-4-[1-(2-pyridyl)-2-hydroxy-ethoxy]pyrazolo[1,5-a]pyridin-6-yl]-5-methyl- triazol-1-yl]piperidine-1 -carbonitrile derivatives with gallic acid and nicotine amide

Publications (1)

Publication Number Publication Date
KR20250057022A true KR20250057022A (ko) 2025-04-28

Family

ID=88204177

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020257010708A Ceased KR20250057022A (ko) 2022-09-07 2023-09-06 4-[4-[3-클로로-4-[1-(2-피리딜)-2-히드록시-에톡시]피라졸로[1,5-a]피리딘-6-일]-5-메틸-트리아졸-1-일]피페리딘-1-카르보니트릴유도체와 갈산 및 니코틴아미드의 공-결정

Country Status (18)

Country Link
US (1) US20240116932A1 (https=)
EP (1) EP4584270A1 (https=)
JP (2) JP7541606B2 (https=)
KR (1) KR20250057022A (https=)
CN (1) CN120187720A (https=)
AR (1) AR130417A1 (https=)
AU (1) AU2023338199A1 (https=)
CA (1) CA3266872A1 (https=)
CL (1) CL2025000596A1 (https=)
CO (1) CO2025002467A2 (https=)
CR (1) CR20250077A (https=)
DO (1) DOP2025000054A (https=)
IL (1) IL319342A (https=)
JO (1) JOP20250053A1 (https=)
MX (1) MX2025002687A (https=)
PE (1) PE20251400A1 (https=)
TW (1) TWI862146B (https=)
WO (1) WO2024054814A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025259519A1 (en) 2024-06-13 2025-12-18 Eli Lilly And Company Activation of egfr/her2/3 in cancer after treatment with an inhibitor of fibroblast growth factor receptor 3 (fgfr3)
WO2026037249A1 (zh) * 2024-08-13 2026-02-19 海思科医药集团股份有限公司 取代杂环类衍生物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1962600B1 (en) * 2005-12-08 2013-05-01 New Form Pharmaceuticals Inc. Metronidazole cocrystals
PH12012000132A1 (en) * 2011-06-09 2014-10-20 Servier Lab New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them
CN102964384B (zh) * 2012-11-09 2015-06-24 中山大学 阿德福韦酯没食子酸共晶及其制备方法和组合物
EP3752159A4 (en) * 2018-02-13 2021-11-24 Transgenex Nanobiotech, Inc. NEW CRYSTALLINE FORMS OF TAMIBAROTENE FOR CANCER TREATMENT
WO2020131627A1 (en) * 2018-12-19 2020-06-25 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
CN111574359A (zh) * 2019-02-19 2020-08-25 愈磐生物科技（苏州）有限公司 乐伐替尼-没食子酸共晶晶型及其应用
CN113943284B (zh) * 2020-07-15 2023-12-19 中国医学科学院药物研究所 盐酸吡格列酮没食子酸共晶及制备方法和其组合物与用途
AR125588A1 (es) * 2021-03-04 2023-08-02 Lilly Co Eli Compuestos inhibidores de fgfr3

Also Published As

Publication number Publication date
WO2024054814A1 (en) 2024-03-14
JP2024037713A (ja) 2024-03-19
CO2025002467A2 (es) 2025-03-17
CN120187720A (zh) 2025-06-20
CR20250077A (es) 2025-04-02
CA3266872A1 (en) 2024-03-14
JOP20250053A1 (ar) 2025-03-06
EP4584270A1 (en) 2025-07-16
JP7541606B2 (ja) 2024-08-28
US20240116932A1 (en) 2024-04-11
AU2023338199A1 (en) 2025-03-20
DOP2025000054A (es) 2025-03-31
CL2025000596A1 (es) 2025-04-25
PE20251400A1 (es) 2025-05-22
JP2024153948A (ja) 2024-10-29
IL319342A (en) 2025-05-01
AR130417A1 (es) 2024-12-04
TWI862146B (zh) 2024-11-11
MX2025002687A (es) 2025-04-02
TW202428260A (zh) 2024-07-16

Similar Documents

Publication Publication Date Title
CN112300173B (zh) 一类含氮多环类化合物、制备方法和用途
CN115322158B (zh) 作为krasg12c蛋白抑制剂的取代喹唑啉类化合物
AU2017284702B2 (en) Pyrrolopyrimidine crystal for preparing JAK inhibitor
CN112608318B (zh) 一种作为蛋白质激酶抑制剂的化合物及其用途
WO2023116895A1 (zh) Kras抑制剂的多晶型物及其制备方法和用途
WO2021238818A1 (zh) 一种大环jak抑制剂及其应用
KR20170032330A (ko) Ｃ-Ｍｅｔ 억제제의 결정질 유리 염기 또는 이의 결정질 산 염, 및 이들의 제조방법 및 용도
TW201704237A (zh) 適用於治療與ｋｉｔ及ｐｄｆｇｒ相關之病症的組合物
JP2024153948A (ja) Ｆｇｆｒ３阻害剤の共結晶形態
KR20090107013A (ko) 티아졸리딘디온 화합물의 결정질 형태 및 이의 제조 방법
JP7802200B2 (ja) 置換のアミノ６員窒素複素環式化合物の塩及びその結晶形、製造方法と応用
CN105218548A (zh) 一种新型杂环化合物及其制备方法和作为激酶抑制剂的用途
CN112110938A (zh) 一种作为蛋白质激酶抑制剂的化合物及其制备方法和用途
CN107200716B (zh) 苯并噁嗪类化合物及其制备方法与应用
TWI786303B (zh) 抑制ｃｄｋ4/6活性化合物的晶型及其應用
AU2020242723B2 (en) BTK inhibitor, pharmaceutically acceptable salt, polymorph and application thereof
CN117800953A (zh) 一种2-芳香胺基嘧啶类化合物及其制备方法与应用
CN111892536B (zh) 取代的喹啉甲酰胺类化合物及其用途
JP2005524671A (ja) 新規アゼパン誘導体類
KR20220159457A (ko) Fgfr4 억제제의 염 형태, 결정 형태 및 그 용도
KR20240007187A (ko) 이미다졸리디논류 화합물의 다형체, 제조 방법 및 이의 용도
CN111875583A (zh) 三氮唑衍生物及其制备方法和用途
KR20220088712A (ko) 화합물의 염 및 이의 결정질 형태
RU2833198C1 (ru) Соль ариламинохиназолин-содержащего соединения и способ ее получения и ее применение
RS61833B1 (sr) Derivati piridohinazolina korisni kao inhibitori proteinske kinaze

Legal Events

Date Code Title Description
A201 Request for examination
A302 Request for accelerated examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000